Cas:1261268-83-0 5-[4-(Methylsulfonamido)phenyl]-2H-tetrazole manufacturer & supplier

Chemical Name:5-[4-(Methylsulfonamido)phenyl]-2H-tetrazole

CAS.NO:1261268-83-0

Synonyms:[6-[3-(trifluoromethyl)phenyl]pyridin-3-yl]methanol

Molecular Formula:C₁₃H₁₀F₃NO

Molecular Weight:253.22000

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:33.12000

Exact Mass:253.07100

LogP:3.25970

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like [6-[3-(trifluoromethyl)phenyl]pyridin-3-yl]methanol chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,[6-[3-(trifluoromethyl)phenyl]pyridin-3-yl]methanol physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,[6-[3-(trifluoromethyl)phenyl]pyridin-3-yl]methanol Use and application,[6-[3-(trifluoromethyl)phenyl]pyridin-3-yl]methanol technical grade,usp/ep/jp grade.

Related News: Novavax, a Maryland biotechnology company that has struggled mightily with delays in developing its coronavirus vaccine, announced Monday that its two-shot regimen was over 90% effective overall in a trial that unfolded even as more contagious variants emerged. 5-[4-(Methylsulfonamido)phenyl]-2H-tetrazole manufacturer Novavax, a Maryland biotechnology company that has struggled mightily with delays in developing its coronavirus vaccine, announced Monday that its two-shot regimen was over 90% effective overall in a trial that unfolded even as more contagious variants emerged. 5-[4-(Methylsulfonamido)phenyl]-2H-tetrazole supplier What is the difference? Raw material refers to chemical compounds that are used as a base to make an API. 5-[4-(Methylsulfonamido)phenyl]-2H-tetrazole vendor For example, an active ingredient to relieve pain is included in a painkiller. 5-[4-(Methylsulfonamido)phenyl]-2H-tetrazole factory Novavax, a Maryland biotechnology company that has struggled mightily with delays in developing its coronavirus vaccine, announced Monday that its two-shot regimen was over 90% effective overall in a trial that unfolded even as more contagious variants emerged.